EXPERIMENTAL ALLERGIC NEURITIS
\ɛkspˌɛɹɪmˈɛntə͡l ɐlˈɜːd͡ʒɪk njuːɹˈa͡ɪtɪs], \ɛkspˌɛɹɪmˈɛntəl ɐlˈɜːdʒɪk njuːɹˈaɪtɪs], \ɛ_k_s_p_ˌɛ_ɹ_ɪ_m_ˈɛ_n_t_əl ɐ_l_ˈɜː_dʒ_ɪ_k n_j_uː_ɹ_ˈaɪ_t_ɪ_s]\
Sort: Oldest first
-
An experimental animal demyelinating disease model of GUILLAINE-BARRE SYNDROME. In the most frequently used protocol, animals are injected with a peripheral nerve tissue protein homogenate. After approximately 2 weeks the animals develop a neuropathy secondary to a T cell-mediated autoimmune response directed towards the MYELIN P2 PROTEIN in peripheral nerves. Pathologic findings include a perivascular accumulation of macrophages and T lymphocytes in the peripheral nervous system, similar to that seen in the Guillaine-Barre syndrome. (From Adams et al., Principles of Neurology, 6th ed, p1314; J Neuroimmunol 1998 Apr 1;84 (1):40-52)
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.